HRT and cancer risk: separating fact from fiction (Q33830916)

29 July 2017

1 reference

title

HRT and cancer risk: separating fact from fiction (English)

1 reference

Hormone Replacement Therapy

29 July 2017

1 reference

Schneider HP

1

1 reference

29 July 2017

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

33 Suppl 1

1 reference

29 July 2017

S65-72

1 reference

Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Estrogen replacement therapy and risk of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Postmenopausal hormone therapy and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Postmenopausal hormone use and risk for colorectal cancer and adenoma

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Estrogen replacement therapy and fatal ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Risk factors for ovarian cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Noncontraceptive estrogen use and epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Epidemiology, prevention, and early detection of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Breast cancer trends. Incidence, mortality, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Hormone therapy following breast and uterine cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Progestin regulation of cellular proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Noncontraceptive hormone use and risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Hormone therapy to prevent disease and prolong life in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

Gynecologic complications of cyclic estrogen progestin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

HRT: an analysis of benefits, risks and costs

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900065-1

7 January 2021

10.1016/S0378-5122(99)00065-1

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10661617